美股大观2019-06-23 13:01
美新|BECL生物制药公司IPO,肿瘤免疫治疗$Atreca(BCEL)$
我们是一家生物制药公司,利用我们的差异化平台发现和开发新型抗体免疫治疗剂,以治疗各种实体肿瘤类型。我们利用我们的药物发现方法来鉴定超过1,400种不同的人类抗体,这些抗体优...查看全文
$Atreca(BCEL)$ DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material Accession Number: 0001104659-24-038606 Act: 34 Size: 21 KB 网页链接
$Atreca(BCEL)$ EFFECT Notice of Effectiveness Accession Number: 9999999995-24-000708 Act: 33 Size: 1 KB 网页链接
$Atreca(BCEL)$ EFFECT Notice of Effectiveness Accession Number: 9999999995-24-000710 Act: 33 Size: 1 KB 网页链接
$Atreca(BCEL)$ POS AM Post-Effective amendments for registration statement Accession Number: 0001104659-24-037501 Act: 33 Size: 23 KB 网页链接
$Atreca(BCEL)$ POS AM Post-Effective amendments for registration statement Accession Number: 0001104659-24-037506 Act: 33 Size: 23 KB 网页链接
$Atreca(BCEL)$ 25 Notification of the removal from listing and registration of matured, redeemed or retired securities Accession Number: 0001104659-24-036738 Act: 34 Size: 12 KB 网页链接
$Atreca(BCEL)$ 8-K Current report, item 3.01 Accession Number: 0001104659-24-032973 Act: 34 Size: 205 KB 网页链接
$Atreca(BCEL)$ DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material Accession Number: 0001104659-24-032980 Act: 34 Size: 32 KB 网页链接
$Atreca(BCEL)$ DEFM14A Definitive proxy statement relating to merger or acquisition Accession Number: 0001104659-24-027127 Act: 34 Size: 2 MB 网页链接
$Atreca(BCEL)$ 8-K Current report, items 5.02 and 9.01 Accession Number: 0001104659-24-011090 Act: 34 Size: 416 KB 网页链接